Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza

TY - JOUR

T1 - Clinical Practice Guidelines by the Infectious Diseases Society of America

T2 - 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza

AU - Uyeki, Timothy M.

AU - Bernstein, Henry H.

AU - Bradley, John S.

AU - Englund, Janet A.

AU - File, Thomas M.

AU - Fry, Alicia M.

AU - Gravenstein, Stefan

AU - Hayden, Frederick G.

AU - Harper, Scott A.

AU - Hirshon, Jon Mark

AU - Ison, Michael G.

AU - Johnston, B. Lynn

AU - Knight, Shandra L.

AU - McGeer, Allison

AU - Riley, Laura E.

AU - Wolfe, Cameron R.

AU - Alexander, Paul E.

AU - Pavia, Andrew T.

N1 - Funding Information: Potential conflicts of interest. The following list is a reflection of what has been reported to the IDSA. To provide thorough transparency, the IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest (COI) is determined by a review process that includes assessment by the Standards and Practice Guidelines Committee (SPGC) Chair, the SPGC liaison to the development panel and the Board of Directors (BOD) liaison to the SPGC, and if necessary, the COI Task Force of the BOD. This assessment of disclosed relationships for possible COI will be based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. H. H. B. reports grants from the New York State Department of Health and personal fees from Current Opinion in Pediatrics, Shire Human Genetic Therapies, the Harvard School of Public Health, and the American Academy of Pediatrics (AAP); H. H. B. is a member of the Advisory Committee on Immunization Practices at CDC; is an ex-officio member of the Committee on Infectious Diseases at AAP; and is an editor of the Red Book Online at AAP. J. A. E. reports personal fees from Sanofi Pasteur, Gilead, and the Bill & Melinda Gates Foundation and grants from Gilead, Chimerix, Novavax, the Bill & Melinda Gates Foundation, Alios/Janssen, and MedImmune, outside the submitted work. T. M. F. reports personal fees from bioMérieux, Curetis AG, GlaxoSmithKline, Melinta, Meji Seika Pharma Co, Merck & Co, MotifBio, Nabriva, Paratek, and Shionogi, during the conduct of the study. S. G. reports grants, personal fees, and nonfinancial support from Sanofi and Seqirus; personal fees from Merck, Pfizer, Longevoron, Janssen, GSK, and the Gerontological Society of America; and grants from the National Institutes of Health (NIH), CDC, and Janssen. F. G. H. reports personal fees from the World Health Organization and the University of Alabama Antiviral Drug Discovery and Development Consortium; other from Celltrion, GSK, Vaccitech, PRE Biopharm, and Seqirus; travel support and donations to a non-profit orphanage and school for consulting; and noncompensated consulting for various companies engaged in developing influenza therapeutics or vaccines (CoCrystal, Farmak, Genentech/Roche, GSK, Janssen, MedImmune, Medivector/FujiFilm, Regeneron, resTORbio, Vir, and Visterra). J. M. H. reports personal fees from Pfizer; nonfinancial support from Global Blood Therapeutics; and grants from the NIH, Fogarty International Center, the Health Resources and Services Administration, the Centers for Medicare and Medicaid, and the Maryland Institute of Emergency Medical System Services, outside the submitted work. M. G. I. reports grants from Janssen and Emergent BioSolutions; personal fees from Celltrion, Genentech/Roche, MediVector, Seqirus, VirBio, Alios, Biota, Crucell, Janssen, and NexBio, during the conduct of the study; and reimbursement for serving on a data safety monitoring board from GlaxoSmithKline. B. L. J. reports grants from Pfizer, Gilead, and the Canadian Institutes of Health Research (CIHR); and contracts for nosocomial infection surveillance from the Public Health Agency of Canada, outside the submitted work. A. M. reports grants and other from Crucell, Sanofi Pasteur, and GlaxoSmithKline; and grants from CIHR and the Ontario Workplace Safety Insurance Board, outside the submitted work. L. E. R. served as a consultant to the Vaccines and Medications in Pregnancy Surveillance System; served as a speaker for the American College of Obstetricians and Gynecologists; served as a contributor for UpToDate; served as a consultant to Johns Hopkins University; reports grants from the Bill & Melinda Gates Foundation; and provided expert testimony for Ficks and Connolly, for Wiggins and Dana, LLP, and for McAloon & Friedman. A. T. P. reports grants from the National Institute of Allergy and Infectious Diseases (NIAID)/NIH, NIAID/Biofire, and the CDC; other from Antimicrobial Therapy Inc; and personal fees from WebMD and Johnson & Johnson, outside the submitted work. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

PY - 2019/3/5

Y1 - 2019/3/5

KW - chemoprophylaxis

KW - diagnostic testing

KW - influenza

KW - institutional outbreaks

KW - seasonal

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85062100120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062100120&partnerID=8YFLogxK

U2 - 10.1093/cid/ciy874

DO - 10.1093/cid/ciy874

M3 - Review article

C2 - 30834445

AN - SCOPUS:85062100120

SN - 1058-4838

VL - 68

SP - 895

EP - 902

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -